At a glance
- Originator Fidia Farmaceutici; Georgetown University School of Medicine
- Developer Nonindustrial source
- Class Antidementias; Antiepileptic drugs; Antiparkinsonians; Neuroprotectants
- Mechanism of Action Excitatory amino acid antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dementia; Epilepsy; Parkinson's disease
Most Recent Events
- 10 Oct 2003 Discontinued - Preclinical for Dementia in USA (unspecified route)
- 10 Oct 2003 Discontinued for Epilepsy in USA (unspecified route)
- 10 Oct 2003 Discontinued for Parkinson's disease in USA (unspecified route)